Literature DB >> 12654698

Pathogenic Nocardia, Rhodococcus, and related organisms are highly susceptible to imidazole antifungals.

Eric R Dabbs1, Samantha Naidoo, Catherine Lephoto, Natalya Nikitina.   

Abstract

Rhodococcus equi and species of Nocardia and Gordonia may be human opportunistic pathogens. We find that these, as well as several isolates from closely related genera, are highly susceptible to the imidazoles bifonazole, clotrimazole, econazole, and miconazole, whose MICs are </=1 micro g/ml. In liquid cultures 1 micro g of the drug/ml was bacteriostatic and 10 micro g/ml was bactericidal. On solid media at 10 micro g of azole/ml no resistant mutants could be isolated. An MIC of 1 to 15 micro g/ml was observed with ketoconazole, whereas none of these organisms was inhibited by the triazoles fluconazole and voriconazole (100 micro g/ml). Imidazoles may offer the prospect of treatment of nocardioform mycetomas and may provide the basis for the development of additional antimicrobial agents to combat these pathogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654698      PMCID: PMC152489          DOI: 10.1128/AAC.47.4.1476-1478.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Disseminated Nocardia Brasiliensis Infection in an Immunocompromised Patient.

Authors: 
Journal:  Cancer Control       Date:  1998-01       Impact factor: 3.302

Review 2.  Pathogenesis and virulence of Rhodococcus equi.

Authors:  M K Hondalus
Journal:  Vet Microbiol       Date:  1997-06-16       Impact factor: 3.293

3.  A cluster of Rhodococcus (Gordona) Bronchialis sternal-wound infections after coronary-artery bypass surgery.

Authors:  H M Richet; P C Craven; J M Brown; B A Lasker; C D Cox; M M McNeil; A D Tice; W R Jarvis; O C Tablan
Journal:  N Engl J Med       Date:  1991-01-10       Impact factor: 91.245

4.  Rhodococcus equi and Nocardia brasiliensis infection of the brain and liver in a patient with acute nonlymphoblastic leukemia.

Authors:  H Akan; M Akova; H Ataoğlu; G Aksu; O Arslan; H Koç
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-10       Impact factor: 3.267

5.  Rhodococcus equi infection in HIV-infected patients.

Authors:  B Clotet; G Sirera; A Erice
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-04

Review 6.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 7.  Rhodococcus equi infection in patients with and without human immunodeficiency virus infection.

Authors:  R L Harvey; J C Sunstrum
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

8.  Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis.

Authors:  C J Jackson; D C Lamb; D E Kelly; S L Kelly
Journal:  FEMS Microbiol Lett       Date:  2000-11-15       Impact factor: 2.742

9.  Action of antifungal imidazoles on Staphylococcus aureus.

Authors:  I J Sud; D S Feingold
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

Review 10.  Primary cutaneous Nocardia otitidiscaviarum infection: case report and review.

Authors:  N M Clark; D K Braun; A Pasternak; C E Chenoweth
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

View more
  2 in total

1.  In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.

Authors:  Lucio Vera-Cabrera; Mayra Paola Campos-Rivera; Wendy G Escalante-Fuentes; Michael J Pucci; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

2.  Imidazole antibiotics inhibit the nitric oxide dioxygenase function of microbial flavohemoglobin.

Authors:  Ryan A Helmick; Arin E Fletcher; Anne M Gardner; Christopher R Gessner; Angela N Hvitved; Michael C Gustin; Paul R Gardner
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.